Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2021-12-15 00:00:00 ET · period of report 2021-12-13 · accession 0001209191-21-069853 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-15 | 2021-12-13 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100 | 23.6K | +0.4% | $0 |
| D | 2021-12-15 | 2021-12-13 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $20.02 | -100 | 23.5K | -0.4% | -$2,002 |
| D | 2021-12-15 | 2021-12-13 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -100 | 8.19M | -0.0% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-12-13 | C | A | 100 | $0.00 | 23,570 | D | — | — | |
| 2 | Common | Class A Common Stock | 2021-12-13 | S | D | 100 | $20.02 | 23,470 | D | — | — | |
| 3 | Derivative | Class B Common Stock | 2021-12-13 | C | D | 100 | $0.00 | 8,194,542 | D | $0.00 · — to — | 100 Class A Common Stock | (F3) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |